ID   FES_HUMAN               Reviewed;         822 AA.
AC   P07332; B2R6E6; B4DUD0; E9PC94; E9PC95; Q2VXS7; Q2VXS8; Q2VXT0;
AC   Q6GTU5;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 3.
DT   10-MAY-2017, entry version 194.
DE   RecName: Full=Tyrosine-protein kinase Fes/Fps;
DE            EC=2.7.10.2;
DE   AltName: Full=Feline sarcoma/Fujinami avian sarcoma oncogene homolog;
DE   AltName: Full=Proto-oncogene c-Fes;
DE   AltName: Full=Proto-oncogene c-Fps;
DE   AltName: Full=p93c-fes;
GN   Name=FES; Synonyms=FPS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2179816;
RA   Alcalay M., Antolini F., van de Ven W.J.M., Lanfrancone L.,
RA   Grignani F., Pelicci P.G.;
RT   "Characterization of human and mouse c-fes cDNA clones and
RT   identification of the 5' end of the gene.";
RL   Oncogene 5:267-275(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=4065096;
RA   Roebroek A.J.M., Schalken J.A., Verbeek J.S., van den Ouweland A.M.W.,
RA   Onnekink C., Bloemers H.P.J., van de Ven W.J.M.;
RT   "The structure of the human c-fes/fps proto-oncogene.";
RL   EMBO J. 4:2897-2903(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4).
RA   Lefebvre J.-C.;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION IN CELL DIFFERENTIATION AND AS TUMOR SUPPRESSOR, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=2656706;
RA   Yu G., Smithgall T.E., Glazer R.I.;
RT   "K562 leukemia cells transfected with the human c-fes gene acquire the
RT   ability to undergo myeloid differentiation.";
RL   J. Biol. Chem. 264:10276-10281(1989).
RN   [9]
RP   PHOSPHORYLATION AT TYR-713, CATALYTIC ACTIVITY, AND MUTAGENESIS OF
RP   TYR-713.
RX   PubMed=7687763;
RA   Hjermstad S.J., Peters K.L., Briggs S.D., Glazer R.I., Smithgall T.E.;
RT   "Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by
RT   its src homology 2 domain and major autophosphorylation site (Tyr-
RT   713).";
RL   Oncogene 8:2283-2292(1993).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF BCR, AUTOPHOSPHORYLATION, AND ENZYME
RP   REGULATION.
RX   PubMed=8955135; DOI=10.1074/jbc.271.51.32930;
RA   Li J., Smithgall T.E.;
RT   "Co-expression with BCR induces activation of the FES tyrosine kinase
RT   and phosphorylation of specific N-terminal BCR tyrosine residues.";
RL   J. Biol. Chem. 271:32930-32936(1996).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11339827; DOI=10.1006/excr.2001.5217;
RA   Zirngibl R., Schulze D., Mirski S.E., Cole S.P., Greer P.A.;
RT   "Subcellular localization analysis of the closely related Fps/Fes and
RT   Fer protein-tyrosine kinases suggests a distinct role for Fps/Fes in
RT   vesicular trafficking.";
RL   Exp. Cell Res. 266:87-94(2001).
RN   [12]
RP   FUNCTION IN CELL PROLIFERATION AND CELL SPREADING, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, SUBUNIT, DOMAIN, AND MUTAGENESIS OF LEU-145 AND
RP   LEU-334.
RX   PubMed=11509660; DOI=10.1128/MCB.21.18.6170-6180.2001;
RA   Cheng H.Y., Schiavone A.P., Smithgall T.E.;
RT   "A point mutation in the N-terminal coiled-coil domain releases c-Fes
RT   tyrosine kinase activity and survival signaling in myeloid leukemia
RT   cells.";
RL   Mol. Cell. Biol. 21:6170-6180(2001).
RN   [13]
RP   REVIEW.
RX   PubMed=11994747; DOI=10.1038/nrm783;
RA   Greer P.;
RT   "Closing in on the biological functions of Fps/Fes and Fer.";
RL   Nat. Rev. Mol. Cell Biol. 3:278-289(2002).
RN   [14]
RP   FUNCTION IN REORGANIZATION OF THE ACTIN CYTOSKELETON AND CELL
RP   DIFFERENTIATION, AND INTERACTION WITH BCR.
RX   PubMed=15302586; DOI=10.1016/j.yexcr.2004.05.010;
RA   Laurent C.E., Smithgall T.E.;
RT   "The c-Fes tyrosine kinase cooperates with the breakpoint cluster
RT   region protein (Bcr) to induce neurite extension in a Rac- and Cdc42-
RT   dependent manner.";
RL   Exp. Cell Res. 299:188-198(2004).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH TUBULIN AND
RP   MICROTUBULES, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-713,
RP   PHOSPHORYLATION BY HCK, AND MUTAGENESIS OF LEU-145; ARG-483 AND
RP   LYS-590.
RX   PubMed=15485904; DOI=10.1128/MCB.24.21.9351-9358.2004;
RA   Laurent C.E., Delfino F.J., Cheng H.Y., Smithgall T.E.;
RT   "The human c-Fes tyrosine kinase binds tubulin and microtubules
RT   through separate domains and promotes microtubule assembly.";
RL   Mol. Cell. Biol. 24:9351-9358(2004).
RN   [16]
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF MET-704;
RP   ARG-706; VAL-743 AND SER-759.
RX   PubMed=15867340; DOI=10.1158/0008-5472.CAN-04-3468;
RA   Sangrar W., Zirgnibl R.A., Gao Y., Muller W.J., Jia Z., Greer P.A.;
RT   "An identity crisis for fps/fes: oncogene or tumor suppressor?";
RL   Cancer Res. 65:3518-3522(2005).
RN   [17]
RP   ALTERNATIVE SPLICING.
RX   PubMed=15869408; DOI=10.1089/dna.2005.24.311;
RA   Carlson A., Berkowitz J.M., Browning D., Slamon D.J., Gasson J.C.,
RA   Yates K.E.;
RT   "Expression of c-Fes protein isoforms correlates with differentiation
RT   in myeloid leukemias.";
RL   DNA Cell Biol. 24:311-316(2005).
RN   [18]
RP   INTERACTION WITH TRIM28.
RX   PubMed=16792528; DOI=10.1042/BJ20060194;
RA   Delfino F.J., Shaffer J.M., Smithgall T.E.;
RT   "The KRAB-associated co-repressor KAP-1 is a coiled-coil binding
RT   partner, substrate and activator of the c-Fes protein tyrosine
RT   kinase.";
RL   Biochem. J. 399:141-150(2006).
RN   [19]
RP   FUNCTION IN STAT3 PHOSPHORYLATION, ROLE AS PUTATIVE TUMOR SUPPRESSOR
RP   IN COLON CANCER, MUTAGENESIS OF MET-704; ARG-706; VAL-743 AND SER-759,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16455651; DOI=10.1074/jbc.M507331200;
RA   Delfino F.J., Stevenson H., Smithgall T.E.;
RT   "A growth-suppressive function for the c-fes protein-tyrosine kinase
RT   in colorectal cancer.";
RL   J. Biol. Chem. 281:8829-8835(2006).
RN   [20]
RP   FUNCTION IN KIT SIGNALING, AND POSSIBLE ROLE IN CANCER CELL
RP   PROLIFERATION.
RX   PubMed=17595334; DOI=10.1182/blood-2007-02-076471;
RA   Voisset E., Lopez S., Dubreuil P., De Sepulveda P.;
RT   "The tyrosine kinase FES is an essential effector of KITD816V
RT   proliferation signal.";
RL   Blood 110:2593-2599(2007).
RN   [21]
RP   FUNCTION IN CYTOSKELETON REORGANIZATION, INTERACTION WITH EZR,
RP   PHOSPHORYLATION AT TYR-713, AND SUBCELLULAR LOCATION.
RX   PubMed=18046454; DOI=10.1038/sj.emboj.7601943;
RA   Naba A., Reverdy C., Louvard D., Arpin M.;
RT   "Spatial recruitment and activation of the Fes kinase by ezrin
RT   promotes HGF-induced cell scattering.";
RL   EMBO J. 27:38-50(2008).
RN   [22]
RP   SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-713,
RP   PHOSPHORYLATION BY HCK, AND DOMAIN.
RX   PubMed=19382747; DOI=10.1021/bi900238f;
RA   Shaffer J.M., Hellwig S., Smithgall T.E.;
RT   "Bimolecular fluorescence complementation demonstrates that the c-Fes
RT   protein-tyrosine kinase forms constitutive oligomers in living
RT   cells.";
RL   Biochemistry 48:4780-4788(2009).
RN   [23]
RP   FUNCTION, TISSUE SPECIFICITY, AND ROLE AS PUTATIVE TUMOR SUPPRESSOR IN
RP   COLON CANCER.
RX   PubMed=19051325; DOI=10.1002/gcc.20638;
RA   Shaffer J.M., Smithgall T.E.;
RT   "Promoter methylation blocks FES protein-tyrosine kinase gene
RT   expression in colorectal cancer.";
RL   Genes Chromosomes Cancer 48:272-284(2009).
RN   [24]
RP   PUTATIVE ROLE IN RENAL CARCINOMA.
RX   PubMed=19082481;
RA   Kanda S., Miyata Y., Kanetake H., Smithgall T.E.;
RT   "Downregulation of the c-Fes protein-tyrosine kinase inhibits the
RT   proliferation of human renal carcinoma cells.";
RL   Int. J. Oncol. 34:89-96(2009).
RN   [25]
RP   FUNCTION, INTERACTION WITH MS4A2/FCER1B AND HCLS1/HS1, SUBCELLULAR
RP   LOCATION, PHOSPHORYLATION, INTERACTION WITH
RP   PHOSPHOINOSITIDE-CONTAINING MEMBRANES, AND MUTAGENESIS OF
RP   113-ARG-LYS-114.
RX   PubMed=19001085; DOI=10.1128/MCB.00904-08;
RA   McPherson V.A., Everingham S., Karisch R., Smith J.A., Udell C.M.,
RA   Zheng J., Jia Z., Craig A.W.;
RT   "Contributions of F-BAR and SH2 domains of Fes protein tyrosine kinase
RT   for coupling to the FcepsilonRI pathway in mast cells.";
RL   Mol. Cell. Biol. 29:389-401(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64; SER-67; TYR-261;
RP   TYR-713 AND SER-716, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   FUNCTION, PHOSPHORYLATION AT THR-421, AND INTERACTION WITH FLT3.
RX   PubMed=20111072; DOI=10.1038/leu.2009.301;
RA   Voisset E., Lopez S., Chaix A., Georges C., Hanssens K., Prebet T.,
RA   Dubreuil P., De Sepulveda P.;
RT   "FES kinases are required for oncogenic FLT3 signaling.";
RL   Leukemia 24:721-728(2010).
RN   [28]
RP   REVIEW.
RX   PubMed=21622225; DOI=10.2741/3902;
RA   Hellwig S., Smithgall T.E.;
RT   "Structure and regulation of the c-Fes protein-tyrosine kinase.";
RL   Front. Biosci. 16:3146-3155(2011).
RN   [29]
RP   POSSIBLE ROLE IN PROSTATE CANCER.
RX   PubMed=21563194; DOI=10.1002/pros.21422;
RA   Miyata Y., Watanabe S.I., Matsuo T., Hayashi T., Sakai H., Xuan J.W.,
RA   Greer P.A., Kanda S.;
RT   "Pathological significance and predictive value for biochemical
RT   recurrence of c-Fes expression in prostate cancer.";
RL   Prostate 72:201-208(2012).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-408 AND SER-411, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   STRUCTURE BY NMR OF 450-550.
RX   PubMed=15929003; DOI=10.1007/s10858-005-0946-6;
RA   Scott A., Pantoja-Uceda D., Koshiba S., Inoue M., Kigawa T.,
RA   Terada T., Shirouzu M., Tanaka A., Sugano S., Yokoyama S.,
RA   Guentert P.;
RT   "Solution structure of the Src homology 2 domain from the human feline
RT   sarcoma oncogene Fes.";
RL   J. Biomol. NMR 31:357-361(2005).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.78 ANGSTROMS) OF 448-822 OF UNPHOSPHORYLATED
RP   APOPROTEIN AND IN COMPLEX WITH STAUROSPORINE AND A SUBSTRATE PEPTIDE,
RP   CATALYTIC ACTIVITY, ENZYME REGULATION, PHOSPHORYLATION AT TYR-713, NMR
RP   SPECTROSCOPY, AND MUTAGENESIS OF GLY-463 AND ARG-483.
RX   PubMed=18775312; DOI=10.1016/j.cell.2008.07.047;
RA   Filippakopoulos P., Kofler M., Hantschel O., Gish G.D., Grebien F.,
RA   Salah E., Neudecker P., Kay L.E., Turk B.E., Superti-Furga G.,
RA   Pawson T., Knapp S.;
RT   "Structural coupling of SH2-kinase domains links Fes and Abl substrate
RT   recognition and kinase activation.";
RL   Cell 134:793-803(2008).
RN   [33]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-85; GLN-246 AND VAL-323.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts downstream of cell
CC       surface receptors and plays a role in the regulation of the actin
CC       cytoskeleton, microtubule assembly, cell attachment and cell
CC       spreading. Plays a role in FCER1 (high affinity immunoglobulin
CC       epsilon receptor)-mediated signaling in mast cells. Acts down-
CC       stream of the activated FCER1 receptor and the mast/stem cell
CC       growth factor receptor KIT. Plays a role in the regulation of mast
CC       cell degranulation. Plays a role in the regulation of cell
CC       differentiation and promotes neurite outgrowth in response to NGF
CC       signaling. Plays a role in cell scattering and cell migration in
CC       response to HGF-induced activation of EZR. Phosphorylates BCR and
CC       down-regulates BCR kinase activity. Phosphorylates HCLS1/HS1,
CC       PECAM1, STAT3 and TRIM28. {ECO:0000269|PubMed:11509660,
CC       ECO:0000269|PubMed:15302586, ECO:0000269|PubMed:15485904,
CC       ECO:0000269|PubMed:16455651, ECO:0000269|PubMed:17595334,
CC       ECO:0000269|PubMed:18046454, ECO:0000269|PubMed:19001085,
CC       ECO:0000269|PubMed:19051325, ECO:0000269|PubMed:20111072,
CC       ECO:0000269|PubMed:2656706, ECO:0000269|PubMed:8955135}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11509660,
CC       ECO:0000269|PubMed:15485904, ECO:0000269|PubMed:15867340,
CC       ECO:0000269|PubMed:18775312, ECO:0000269|PubMed:2656706,
CC       ECO:0000269|PubMed:7687763}.
CC   -!- ENZYME REGULATION: Kinase activity is tightly regulated. Activated
CC       in response to signaling from a cell surface receptor. Activation
CC       probably requires binding of a substrate via the SH2 domain, plus
CC       autophosphorylation at Tyr-713. Present in an inactive form in the
CC       absence of activating stimuli. {ECO:0000269|PubMed:18775312,
CC       ECO:0000269|PubMed:8955135}.
CC   -!- SUBUNIT: Homooligomer. Interacts with BCR. Interacts (when
CC       activated, via coiled coil domain) with TRIM28. Interacts (via SH2
CC       domain) with phosphorylated EZR, MS4A2/FCER1B and HCLS1/HS1.
CC       Interacts with phosphorylated KIT. Interacts with FLT3. Interacts
CC       (via F-BAR domain) with soluble tubulin. Interacts (via SH2
CC       domain) with microtubules. {ECO:0000269|PubMed:11509660,
CC       ECO:0000269|PubMed:15302586, ECO:0000269|PubMed:15485904,
CC       ECO:0000269|PubMed:16792528, ECO:0000269|PubMed:18046454,
CC       ECO:0000269|PubMed:18775312, ECO:0000269|PubMed:19001085,
CC       ECO:0000269|PubMed:19382747, ECO:0000269|PubMed:20111072}.
CC   -!- INTERACTION:
CC       P10275:AR; NbExp=3; IntAct=EBI-1055635, EBI-608057;
CC       P15311:EZR; NbExp=8; IntAct=EBI-1055635, EBI-1056902;
CC       Q13480:GAB1; NbExp=2; IntAct=EBI-1055635, EBI-517684;
CC       P10721:KIT; NbExp=2; IntAct=EBI-1055635, EBI-1379503;
CC       P54274:TERF1; NbExp=2; IntAct=EBI-1055635, EBI-710997;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cytoplasm, cytoskeleton.
CC       Cell membrane; Peripheral membrane protein; Cytoplasmic side.
CC       Cytoplasmic vesicle. Golgi apparatus. Cell junction, focal
CC       adhesion. Note=Distributed throughout the cytosol when the kinase
CC       is not activated. Association with microtubules requires
CC       activation of the kinase activity. Shuttles between focal
CC       adhesions and cell-cell contacts in epithelial cells. Recruited to
CC       the lateral cell membrane in polarized epithelial cells by
CC       interaction with phosphorylated EZR. Detected at tubular membrane
CC       structures in the cytoplasm and at the cell periphery.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P07332-1; Sequence=Displayed;
CC       Name=2; Synonyms=Variant 1;
CC         IsoId=P07332-2; Sequence=VSP_041748, VSP_041749;
CC       Name=3; Synonyms=Variant 3;
CC         IsoId=P07332-3; Sequence=VSP_041748;
CC       Name=4; Synonyms=Variant 4;
CC         IsoId=P07332-4; Sequence=VSP_041749;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Detected in adult colon
CC       epithelium. {ECO:0000269|PubMed:16455651,
CC       ECO:0000269|PubMed:19051325}.
CC   -!- DOMAIN: The coiled coil domains are important for regulating the
CC       kinase activity. They mediate homooligomerization and probably
CC       also interaction with other proteins.
CC   -!- DOMAIN: The N-terminal region including the first coiled coil
CC       domain mediates interaction with phosphoinositide-containing
CC       membranes.
CC   -!- PTM: Autophosphorylated on Tyr-713. Phosphorylated by LYN in
CC       response to FCER1 activation. Phosphorylated by HCK.
CC       {ECO:0000269|PubMed:15485904, ECO:0000269|PubMed:18046454,
CC       ECO:0000269|PubMed:18775312, ECO:0000269|PubMed:19001085,
CC       ECO:0000269|PubMed:19382747, ECO:0000269|PubMed:20111072,
CC       ECO:0000269|PubMed:7687763}.
CC   -!- DISEASE: Note=Has been shown to act as proto-oncogene in some
CC       types of cancer, possibly due to abnormal activation of the
CC       kinase. Has been shown to act as tumor suppressor in other types
CC       of cancer. Expressed and present as activated kinase in a subset
CC       of acute myeloid leukemia patients; promotes survival of leukemia
CC       cells (PubMed:20111072). Expression is absent in K562 leukemia
CC       cells; ectopic expression of FSP/FES restores myeloid
CC       differentiation (PubMed:2656706). May function as tumor suppressor
CC       in colorectal cancer; expression is reduced or absent in samples
CC       from some colon cancer patients (PubMed:16455651). Ectopic
CC       expression of FSP/FES suppresses anchorage-independent growth in
CC       colon cancer cell lines (PubMed:16455651). Up-regulated in
CC       prostate cancer, and might be a predictor of recurrence after
CC       radical surgery (PubMed:21563194). May promote growth of renal
CC       carcinoma cells (PubMed:19082481). {ECO:0000269|PubMed:16455651,
CC       ECO:0000269|PubMed:19082481, ECO:0000269|PubMed:20111072,
CC       ECO:0000269|PubMed:21563194, ECO:0000269|PubMed:2656706}.
CC   -!- MISCELLANEOUS: Cellular homolog of retroviral oncogenes. In
CC       contrast to the viral oncoproteins, the kinase activity of
CC       cellular FSP/FES is tightly regulated, and the kinase is inactive
CC       in normal cells in the absence of activating stimuli
CC       (PubMed:15485904). {ECO:0000305|PubMed:15485904}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fes/fps subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52192; CAA36438.1; -; mRNA.
DR   EMBL; X06292; CAA29619.1; -; Genomic_DNA.
DR   EMBL; AY513654; AAS82866.1; -; mRNA.
DR   EMBL; AY513656; AAS82868.1; -; mRNA.
DR   EMBL; AY513657; AAS82869.1; -; mRNA.
DR   EMBL; AK300595; BAG62292.1; -; mRNA.
DR   EMBL; AK312545; BAG35443.1; -; mRNA.
DR   EMBL; AC124248; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471101; EAX02114.1; -; Genomic_DNA.
DR   EMBL; BC035357; AAH35357.1; -; mRNA.
DR   CCDS; CCDS10365.1; -. [P07332-1]
DR   CCDS; CCDS45349.1; -. [P07332-4]
DR   CCDS; CCDS45350.1; -. [P07332-3]
DR   CCDS; CCDS45351.1; -. [P07332-2]
DR   PIR; A24673; TVHUFF.
DR   RefSeq; NP_001137255.1; NM_001143783.1. [P07332-3]
DR   RefSeq; NP_001137256.1; NM_001143784.1. [P07332-4]
DR   RefSeq; NP_001137257.1; NM_001143785.1. [P07332-2]
DR   RefSeq; NP_001996.1; NM_002005.3. [P07332-1]
DR   RefSeq; XP_005254937.1; XM_005254880.1. [P07332-3]
DR   RefSeq; XP_005254939.1; XM_005254882.1. [P07332-4]
DR   RefSeq; XP_016877494.1; XM_017022005.1. [P07332-1]
DR   RefSeq; XP_016877495.1; XM_017022006.1. [P07332-3]
DR   RefSeq; XP_016877496.1; XM_017022007.1. [P07332-4]
DR   RefSeq; XP_016877497.1; XM_017022008.1. [P07332-2]
DR   RefSeq; XP_016877498.1; XM_017022009.1. [P07332-1]
DR   RefSeq; XP_016877499.1; XM_017022010.1. [P07332-3]
DR   UniGene; Hs.7636; -.
DR   PDB; 1WQU; NMR; -; A=450-550.
DR   PDB; 2DCR; NMR; -; A=450-550.
DR   PDB; 3BKB; X-ray; 1.78 A; A=448-822.
DR   PDB; 3CBL; X-ray; 1.75 A; A=448-822.
DR   PDB; 3CD3; X-ray; 1.98 A; A=448-822.
DR   PDB; 4DYL; X-ray; 2.18 A; A=1-405.
DR   PDB; 4E93; X-ray; 1.84 A; A=448-822.
DR   PDBsum; 1WQU; -.
DR   PDBsum; 2DCR; -.
DR   PDBsum; 3BKB; -.
DR   PDBsum; 3CBL; -.
DR   PDBsum; 3CD3; -.
DR   PDBsum; 4DYL; -.
DR   PDBsum; 4E93; -.
DR   ProteinModelPortal; P07332; -.
DR   SMR; P07332; -.
DR   BioGrid; 108533; 25.
DR   IntAct; P07332; 22.
DR   MINT; MINT-1497714; -.
DR   STRING; 9606.ENSP00000331504; -.
DR   BindingDB; P07332; -.
DR   ChEMBL; CHEMBL5455; -.
DR   GuidetoPHARMACOLOGY; 2023; -.
DR   iPTMnet; P07332; -.
DR   PhosphoSitePlus; P07332; -.
DR   BioMuta; FES; -.
DR   DMDM; 115502390; -.
DR   EPD; P07332; -.
DR   MaxQB; P07332; -.
DR   PaxDb; P07332; -.
DR   PeptideAtlas; P07332; -.
DR   PRIDE; P07332; -.
DR   DNASU; 2242; -.
DR   Ensembl; ENST00000328850; ENSP00000331504; ENSG00000182511. [P07332-1]
DR   Ensembl; ENST00000394300; ENSP00000377837; ENSG00000182511. [P07332-3]
DR   Ensembl; ENST00000414248; ENSP00000414629; ENSG00000182511. [P07332-2]
DR   Ensembl; ENST00000444422; ENSP00000400868; ENSG00000182511. [P07332-4]
DR   GeneID; 2242; -.
DR   KEGG; hsa:2242; -.
DR   UCSC; uc002bpv.4; human. [P07332-1]
DR   CTD; 2242; -.
DR   DisGeNET; 2242; -.
DR   GeneCards; FES; -.
DR   HGNC; HGNC:3657; FES.
DR   HPA; HPA001376; -.
DR   MIM; 190030; gene.
DR   neXtProt; NX_P07332; -.
DR   OpenTargets; ENSG00000182511; -.
DR   PharmGKB; PA28098; -.
DR   eggNOG; KOG0194; Eukaryota.
DR   eggNOG; ENOG410Y6RP; LUCA.
DR   GeneTree; ENSGT00760000119011; -.
DR   HOVERGEN; HBG005655; -.
DR   InParanoid; P07332; -.
DR   KO; K07527; -.
DR   OMA; EGFPSIP; -.
DR   OrthoDB; EOG091G01S4; -.
DR   PhylomeDB; P07332; -.
DR   TreeFam; TF315363; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-HSA-399955; SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion.
DR   Reactome; R-HSA-399956; CRMPs in Sema3A signaling.
DR   SignaLink; P07332; -.
DR   SIGNOR; P07332; -.
DR   EvolutionaryTrace; P07332; -.
DR   GeneWiki; Feline_sarcoma_oncogene; -.
DR   GenomeRNAi; 2242; -.
DR   PRO; PR:P07332; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000182511; -.
DR   CleanEx; HS_FES; -.
DR   ExpressionAtlas; P07332; baseline and differential.
DR   Genevisible; P07332; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0034987; F:immunoglobulin receptor binding; IDA:UniProtKB.
DR   GO; GO:0008017; F:microtubule binding; IEA:Ensembl.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0035091; F:phosphatidylinositol binding; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0051297; P:centrosome organization; IEA:Ensembl.
DR   GO; GO:0006935; P:chemotaxis; IBA:GO_Central.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0001578; P:microtubule bundle formation; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0031116; P:positive regulation of microtubule polymerization; IMP:UniProtKB.
DR   GO; GO:0045639; P:positive regulation of myeloid cell differentiation; IMP:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0030155; P:regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; IMP:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0043304; P:regulation of mast cell degranulation; IMP:UniProtKB.
DR   GO; GO:0060627; P:regulation of vesicle-mediated transport; TAS:UniProtKB.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR027267; AH/BAR-dom.
DR   InterPro; IPR031160; F_BAR.
DR   InterPro; IPR001060; FCH_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR016250; Tyr-prot_kinase_Fes/Fps.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PIRSF; PIRSF000632; TyrPK_fps; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00055; FCH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF103657; SSF103657; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51741; F_BAR; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell junction;
KW   Cell membrane; Coiled coil; Complete proteome; Cytoplasm;
KW   Cytoplasmic vesicle; Cytoskeleton; Golgi apparatus; Kinase;
KW   Lipid-binding; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome; SH2 domain;
KW   Transferase; Tumor suppressor; Tyrosine-protein kinase.
FT   CHAIN         1    822       Tyrosine-protein kinase Fes/Fps.
FT                                /FTId=PRO_0000088088.
FT   DOMAIN        1    260       F-BAR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01077}.
FT   DOMAIN      460    549       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      561    822       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     567    575       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        1    300       Important for interaction with membranes
FT                                containing phosphoinositides.
FT   COILED      125    169       {ECO:0000255}.
FT   COILED      324    368       {ECO:0000255}.
FT   ACT_SITE    683    683       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     590    590       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      64     64       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES      67     67       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     261    261       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     408    408       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     411    411       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     421    421       Phosphothreonine.
FT                                {ECO:0000269|PubMed:20111072}.
FT   MOD_RES     713    713       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:15485904,
FT                                ECO:0000269|PubMed:18046454,
FT                                ECO:0000269|PubMed:18775312,
FT                                ECO:0000269|PubMed:19382747,
FT                                ECO:0000269|PubMed:7687763}.
FT   MOD_RES     716    716       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   VAR_SEQ      72    129       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_041748.
FT   VAR_SEQ     441    510       Missing (in isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_041749.
FT   VARIANT      85     85       R -> C (in dbSNP:rs56041861).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041697.
FT   VARIANT     246    246       R -> Q (in dbSNP:rs34573430).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041698.
FT   VARIANT     323    323       M -> V (in dbSNP:rs56296062).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041699.
FT   MUTAGEN     113    114       RK->EE: Reduced binding to membranes
FT                                containing phosphoinositides.
FT                                {ECO:0000269|PubMed:19001085}.
FT   MUTAGEN     113    114       RK->QQ: Reduced binding to membranes
FT                                containing phosphoinositides.
FT                                {ECO:0000269|PubMed:19001085}.
FT   MUTAGEN     145    145       L->P: Constitutively activated kinase
FT                                that can act as oncogene. Promotes
FT                                myeloid cell survival and proliferation.
FT                                {ECO:0000269|PubMed:11509660,
FT                                ECO:0000269|PubMed:15485904}.
FT   MUTAGEN     334    334       L->P: Abolishes autophosphorylation.
FT                                {ECO:0000269|PubMed:11509660}.
FT   MUTAGEN     463    463       G->V: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:18775312}.
FT   MUTAGEN     483    483       R->M: Abolishes pTyr binding. Abolishes
FT                                association with microtubules. Abolishes
FT                                autophosphorylation. Reduced kinase
FT                                activity. {ECO:0000269|PubMed:15485904,
FT                                ECO:0000269|PubMed:18775312}.
FT   MUTAGEN     590    590       K->E: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:15485904}.
FT   MUTAGEN     704    704       M->V: Reduced autophosphorylation and
FT                                strongly reduced kinase activity.
FT                                {ECO:0000269|PubMed:15867340,
FT                                ECO:0000269|PubMed:16455651}.
FT   MUTAGEN     706    706       R->Q: Negligible effect on
FT                                autophosphorylation and kinase activity.
FT                                {ECO:0000269|PubMed:15867340,
FT                                ECO:0000269|PubMed:16455651}.
FT   MUTAGEN     713    713       Y->F: Reduces kinase activity by over
FT                                90%. {ECO:0000269|PubMed:7687763}.
FT   MUTAGEN     743    743       V->M: Strongly reduced
FT                                autophosphorylation and kinase activity.
FT                                {ECO:0000269|PubMed:15867340,
FT                                ECO:0000269|PubMed:16455651}.
FT   MUTAGEN     759    759       S->F: Reduced autophosphorylation and
FT                                strongly reduced kinase activity.
FT                                {ECO:0000269|PubMed:15867340,
FT                                ECO:0000269|PubMed:16455651}.
FT   CONFLICT    719    719       L -> S (in Ref. 1; CAA36438 and 3;
FT                                AAS82866/AAS82869/AAS82868).
FT                                {ECO:0000305}.
FT   HELIX         3      6       {ECO:0000244|PDB:4DYL}.
FT   HELIX        10     51       {ECO:0000244|PDB:4DYL}.
FT   HELIX        68     96       {ECO:0000244|PDB:4DYL}.
FT   HELIX        98    131       {ECO:0000244|PDB:4DYL}.
FT   HELIX       133    154       {ECO:0000244|PDB:4DYL}.
FT   HELIX       167    202       {ECO:0000244|PDB:4DYL}.
FT   HELIX       204    234       {ECO:0000244|PDB:4DYL}.
FT   STRAND      236    238       {ECO:0000244|PDB:4DYL}.
FT   HELIX       239    254       {ECO:0000244|PDB:4DYL}.
FT   HELIX       257    259       {ECO:0000244|PDB:4DYL}.
FT   HELIX       262    268       {ECO:0000244|PDB:4DYL}.
FT   TURN        300    302       {ECO:0000244|PDB:4DYL}.
FT   HELIX       303    344       {ECO:0000244|PDB:4DYL}.
FT   HELIX       350    353       {ECO:0000244|PDB:4DYL}.
FT   HELIX       354    389       {ECO:0000244|PDB:4DYL}.
FT   TURN        390    393       {ECO:0000244|PDB:4DYL}.
FT   HELIX       450    452       {ECO:0000244|PDB:3CBL}.
FT   HELIX       455    457       {ECO:0000244|PDB:3CBL}.
FT   STRAND      461    464       {ECO:0000244|PDB:1WQU}.
FT   HELIX       467    473       {ECO:0000244|PDB:3CBL}.
FT   STRAND      479    484       {ECO:0000244|PDB:3CBL}.
FT   TURN        486    489       {ECO:0000244|PDB:3BKB}.
FT   STRAND      491    494       {ECO:0000244|PDB:3CBL}.
FT   STRAND      503    506       {ECO:0000244|PDB:3CBL}.
FT   STRAND      507    509       {ECO:0000244|PDB:3BKB}.
FT   STRAND      512    517       {ECO:0000244|PDB:3BKB}.
FT   STRAND      520    522       {ECO:0000244|PDB:3BKB}.
FT   HELIX       523    533       {ECO:0000244|PDB:3CBL}.
FT   TURN        539    541       {ECO:0000244|PDB:3BKB}.
FT   HELIX       558    560       {ECO:0000244|PDB:3CBL}.
FT   STRAND      561    570       {ECO:0000244|PDB:3CBL}.
FT   STRAND      573    580       {ECO:0000244|PDB:3CBL}.
FT   TURN        581    583       {ECO:0000244|PDB:3CBL}.
FT   STRAND      586    591       {ECO:0000244|PDB:3CBL}.
FT   HELIX       598    601       {ECO:0000244|PDB:3CBL}.
FT   HELIX       602    605       {ECO:0000244|PDB:3CBL}.
FT   HELIX       606    611       {ECO:0000244|PDB:3CBL}.
FT   STRAND      622    626       {ECO:0000244|PDB:3CBL}.
FT   STRAND      628    631       {ECO:0000244|PDB:3CBL}.
FT   STRAND      633    637       {ECO:0000244|PDB:3CBL}.
FT   HELIX       644    651       {ECO:0000244|PDB:3CBL}.
FT   HELIX       652    654       {ECO:0000244|PDB:3CBL}.
FT   HELIX       657    676       {ECO:0000244|PDB:3CBL}.
FT   HELIX       686    688       {ECO:0000244|PDB:3CBL}.
FT   STRAND      689    691       {ECO:0000244|PDB:3CBL}.
FT   STRAND      697    699       {ECO:0000244|PDB:3CBL}.
FT   HELIX       702    704       {ECO:0000244|PDB:3CBL}.
FT   STRAND      711    714       {ECO:0000244|PDB:3CBL}.
FT   STRAND      720    723       {ECO:0000244|PDB:3CBL}.
FT   HELIX       724    726       {ECO:0000244|PDB:3CBL}.
FT   HELIX       729    734       {ECO:0000244|PDB:3CBL}.
FT   STRAND      736    738       {ECO:0000244|PDB:3CBL}.
FT   HELIX       739    754       {ECO:0000244|PDB:3CBL}.
FT   TURN        755    757       {ECO:0000244|PDB:4E93}.
FT   HELIX       766    774       {ECO:0000244|PDB:3CBL}.
FT   HELIX       787    796       {ECO:0000244|PDB:3CBL}.
FT   HELIX       801    803       {ECO:0000244|PDB:3CBL}.
FT   HELIX       807    820       {ECO:0000244|PDB:3CBL}.
SQ   SEQUENCE   822 AA;  93497 MW;  4C2A90555857F045 CRC64;
     MGFSSELCSP QGHGVLQQMQ EAELRLLEGM RKWMAQRVKS DREYAGLLHH MSLQDSGGQS
     RAISPDSPIS QSWAEITSQT EGLSRLLRQH AEDLNSGPLS KLSLLIRERQ QLRKTYSEQW
     QQLQQELTKT HSQDIEKLKS QYRALARDSA QAKRKYQEAS KDKDRDKAKD KYVRSLWKLF
     AHHNRYVLGV RAAQLHHQHH HQLLLPGLLR SLQDLHEEMA CILKEILQEY LEISSLVQDE
     VVAIHREMAA AAARIQPEAE YQGFLRQYGS APDVPPCVTF DESLLEEGEP LEPGELQLNE
     LTVESVQHTL TSVTDELAVA TEMVFRRQEM VTQLQQELRN EEENTHPRER VQLLGKRQVL
     QEALQGLQVA LCSQAKLQAQ QELLQTKLEH LGPGEPPPVL LLQDDRHSTS SSEQEREGGR
     TPTLEILKSH ISGIFRPKFS LPPPLQLIPE VQKPLHEQLW YHGAIPRAEV AELLVHSGDF
     LVRESQGKQE YVLSVLWDGL PRHFIIQSLD NLYRLEGEGF PSIPLLIDHL LSTQQPLTKK
     SGVVLHRAVP KDKWVLNHED LVLGEQIGRG NFGEVFSGRL RADNTLVAVK SCRETLPPDL
     KAKFLQEARI LKQYSHPNIV RLIGVCTQKQ PIYIVMELVQ GGDFLTFLRT EGARLRVKTL
     LQMVGDAAAG MEYLESKCCI HRDLAARNCL VTEKNVLKIS DFGMSREEAD GVYAASGGLR
     QVPVKWTAPE ALNYGRYSSE SDVWSFGILL WETFSLGASP YPNLSNQQTR EFVEKGGRLP
     CPELCPDAVF RLMEQCWAYE PGQRPSFSTI YQELQSIRKR HR
//
